LAUREN SULLIVAN: Open Payments
NPI 1902685530 · COLUMBUS, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,431 in 77 payments from 12 companies in 2025. Trend: 2023 $0 · 2024 $274 · 2025 $1,431
Food & beverage: $1,431
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 12 | $273 |
| Madrigal Pharmaceuticals | 12 | $212 |
| ABBVIE INC. | 14 | $183 |
| QOL Medical, LLC | 7 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $161 |
| Ardelyx, Inc. | 5 | $124 |
| Aimmune Therapeutics, Inc. | 7 | $112 |
| Janssen Biotech, Inc. | 5 | $100 |
| Intercept Pharmaceuticals, Inc. | 2 | $35 |
| Lilly USA, LLC | 2 | $30 |
Products named: DUPIXENT, REZDIFFRA, Sucraid, ENTYVIO, IBSRELA, TREMFYA, ZENPEP, RINVOQ.
Industry payments across MS — which companies pay providers there.
